- Gilead Sciences, headquartered in Foster City, California, is a leading biopharmaceutical company known for its innovative treatments in HIV and oncology, particularly with its recent focus on CAR-T therapies for cancer.
- In 2026, Gilead made significant moves by acquiring Arcellx for $7.8 billion to gain full control of the anito-cel CAR-T therapy and Tubulis GmbH for $3.15 billion, marking a $16 billion investment in just 60 days.
- Key partnerships include Gilead's collaboration with Kite, which is focused on developing the anito-cel therapy for multiple myeloma, enhancing their oncology pipeline.
- Gilead's ideal buyers are healthcare providers and institutions looking for advanced cancer therapies, as the company addresses the critical need for effective treatments in relapsed and refractory multiple myeloma.
Gilead Sciences employs a diverse workforce across 19 departments, with Operations leading at 1,184 employees, followed by the Executive department with 972. Information Technology also plays a significant role, housing 838 employees. The balance across departments indicates a strong emphasis on operational efficiency and technological support, essential for a pharmaceutical company. Other departments, such as Community and Social Services and Engineering, further contribute to the company's holistic approach to healthcare solutions.
The workforce is primarily concentrated in California, with San Mateo housing the largest group at 1,941 employees. Other notable locations include San Dimas and South San Francisco, with 209 and 127 employees, respectively. The 'Other' category accounts for a significant portion of the workforce, indicating a distributed presence across various regions. This geographic distribution underscores Gilead's commitment to accessibility and local engagement in its operations.
